

Obinutuzumab Biosimilar - Research Grade ICH4026

Product Information

| | |
|-----------------------------|---|
| Catalog Number: | ICH4026 |
| Product: | Low endotoxin, biosimilar antibody |
| Target: | CD20 |
| Isotype: | IgG1 |
| Other names: | B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, MS4A1, afutuzumab |
| Host: | Humanized |
| Species Reactivity: | Human |
| Specificity: | Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Obinutuzumab/afutuzumab. |
| Purification method: | This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. |
| Concentration: | 1.0 - 5.0 mg/ml |
| Formulation: | Phosphate buffered saline (PBS) pH 7.2, with no carrier protein, potassium or preservatives added. BSA and Azide free. |
| Purity: | >95% by SDS-PAGE and HPLC |
| Endotoxin: | ≤ 0.75 EU/mg as determined by the LAL method |
| Storage: | Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |

Background:

Obinutuzumab biosimilar is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B cells. The molecular mass of the antibody is approximately 150 kDa. It is produced by mammalian cell (CHO) suspension culture. It was engineered for reduced fucose content as compared to a typical IgG1 produced in CHO cells.